VieCure is a technology company.
VieCure has raised $70.0M across 2 funding rounds.
VieCure has raised $70.0M in total across 2 funding rounds.
VieCure has raised $70.0M in total across 2 funding rounds.
VieCure's investors include Crosslink Capital, E14 Fund, Gaingels, Northpond Ventures.
VieCure is a technology company founded in 2015 and headquartered in Greenwood Village, Colorado, that develops an AI-powered informatics platform for oncology care.[2][4] The VieCure platform acts as a real-time clinical decision support system and operating system for cancer centers, combining a knowledge base of over 5,000 clinical rules, patient data, an AI inference engine, and tools like a smart EMR, tele-oncology, voice automation, and patient mobile app to generate personalized treatment plans and manage care from diagnosis through follow-up.[1][3][4] It serves oncologists, hematologists, nurses, pharmacists, and patients in community oncology settings across 80+ cancer center locations with 280+ providers, addressing the shift to precision oncology by simplifying complex decision-making and improving outcomes.[1][4] With $70M in total funding, including a $45M round, VieCure shows strong growth momentum through integrations like e-prescribing and patents for customizable treatment plans.[2]
VieCure emerged in 2015 amid the rise of precision medicine, which was overwhelming community oncologists with exploding complexities in cancer care.[2][5] The company was founded by a team with over 100 years of combined cancer leadership experience, motivated by sub-optimal status quo care in community settings and the need for an active assistant platform.[4][5] Early focus centered on building a proprietary AI informatics software with a clinical inference engine and smart oncology EMR to help clinicians adopt evidence-based precision oncology.[1][2] Pivotal moments include securing a $25M Series A led by Northpond Ventures to scale AI and patient-focused tech, expanding contracts to U.S., Bahamas, and Antigua cancer centers, and forging alliances with pharma and diagnostics firms; recent traction involves a U.S. patent for personalized treatment plans and integrations like DrFirst e-prescribing.[1][2]
VieCure stands out in oncology software through its comprehensive, integrated ecosystem tailored for precision medicine:
| Feature | VieCure | Competitors |
|---|---|---|
| AI Clinical Inference | Yes | No |
| Integrated Tele-oncology | Yes | No |
| Voice Automation | Yes | No |
| Precision Oncology/NGS | Yes | No |[4]
VieCure rides the precision oncology wave, where genomic data (e.g., NGS), targeted therapies, and clinical trials demand real-time, data-driven decisions amid clinician shortages and rising cancer burdens.[1][5] Timing aligns with AI's maturation in healthcare, enabling inference engines to codify vast knowledge and ingest disparate sources, while payer rules and prior auth add complexity that VieCure automates.[3] Market forces like pharma alliances, global expansion, and community oncology's need for affordable, scalable tools favor it—positioning VieCure as an ecosystem hub that influences care standardization, trial matching, and outcomes data sharing.[1][3] By empowering 280+ providers across 80+ sites, it accelerates precision medicine adoption beyond academic centers, bridging tech and clinical gaps.[4]
VieCure is poised to dominate community oncology as the go-to operating system, with next steps likely including deeper AI enhancements, international scaling, and more pharma integrations to capture growing precision care demand.[1][2] Trends like multimodal data fusion, remote monitoring mandates, and value-based payer shifts will amplify its edge, potentially driving acquisition interest or further funding.[3] Its influence may evolve from decision support to full care orchestration, humanizing complex cancer journeys—echoing its origin as a clinician's superpower in an era of overwhelming precision demands.[5]
VieCure has raised $70.0M across 2 funding rounds. Most recently, it raised $45.0M Venture Round in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $45.0M Venture Round | Crosslink Capital, E14 Fund, Gaingels, Northpond Ventures | |
| Apr 1, 2021 | $25.0M Series A | Crosslink Capital, E14 Fund, Gaingels, Northpond Ventures |